debt_leverage_profile
Effectively debt-free; cash-funded clinical-stage biotech with no significant long-term debt as of recent filings
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal; no material floating-rate debt exposure; rising rates marginally reduce returns on cash/equivalents holdings
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
API oligonucleotide synthesis (limited CMOs) and liposomal nanoparticle formulation manufacturing concentration in North America
Inferred
Agent_Inference
international_expansion_readiness
Negligible; no meaningful international revenue; all operations and trials primarily US-based with no currency devaluation exposure
Inferred
Agent_Inference
geographic_footprint
Effectively 100% US-based; no material foreign revenue markets; currency devaluation risk is essentially zero
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
High dependency on single-source CMO for DNAbilize liposomal formulation; substitution would require 12–24 months regulatory revalidation
Inferred
Agent_Inference
business_model_type_primary
Cloud infrastructure not a primary operational dependency; research/data workloads minimal; 30-day termination risk is low-impact
Inferred
Agent_Inference
business_model_type_secondary
Pre-commercial clinical-stage biotech; no SaaS, subscription, or cloud-delivered product; secondary model is grant/collaboration funding
Inferred
Agent_Inference
switching_cost_profile
No significant API coupling risk; proprietary drug delivery platform is internal IP, not third-party API-dependent
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; equity securities in a clinical-stage pharma; revenue model is drug licensing/royalties, not investment contracts
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Low GDPR/CCPA exposure; clinical trial patient data governed by HIPAA/ICH-GCP; limited consumer PII handled commercially
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible antitrust risk; pre-revenue niche oncology/hematology pipeline with no dominant market position
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~100% non-recurring; revenue is grant income and occasional collaboration payments; no subscription or multi-year contracted revenue
Inferred
Agent_Inference
monetization_vector
Future monetization via drug licensing deals, royalties on approved products, or outright acquisition by larger pharma
Inferred
Agent_Inference
pricing_architecture
No commercial pricing architecture yet; future drug pricing subject to oncology market comps (~$100K–$300K/patient/year typical)
Inferred
Agent_Inference
pricing_power_rating
Potential high pricing power if approved (orphan oncology niche), but entirely contingent on clinical success and FDA approval
Inferred
Agent_Inference
target_gross_margin_bracket
Target gross margins 70–85% post-commercialization, consistent with licensed biotech/specialty pharma royalty structures
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider or churn risk; pre-commercial with no paying customers; pipeline attrition (trial failure) is the analogous risk
Inferred
Agent_Inference
headcount_cost_structure
Headcount-linear at current scale; ~15–25 FTEs; revenue growth would require CRO/CMO scale-out, not proportional internal hiring
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth is high in development phase (trial costs); post-licensing, incremental cost drops sharply (royalty model)
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC irrelevant pre-commercialization; licensing deal economics depend on pharma partner BD costs, not traditional CAC
Inferred
Agent_Inference
network_effect_present
No network effects; drug pipeline value is IP-driven, not user-base-driven; durability depends on patent protection through ~2035
Inferred
Agent_Inference
asset_efficiency_ratio
-254.8% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate resilience; oncology drugs are non-discretionary, but funding reliance on equity markets makes capital raises recession-sensitive
Inferred
Agent_Inference
customer_segment_primary
Institutional pharma/biotech licensing partners and NIH/grant agencies as primary 'customers' in pre-commercial stage
Inferred
Agent_Inference
customer_segment_secondary
Future end customers are oncology/hematology patients and hospital systems in acute myeloid leukemia and related indications
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated overwhelmingly to R&D and clinical trials (~85–90% of spend); minimal legacy infrastructure; no material capex reallocation needed
Inferred
Agent_Inference
sec_cik
0001133818
High
SEC-EDGAR
ticker
BPTH
High
SEC-EDGAR